News|Articles|November 18, 2026

Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives

Fact checked by: Ashley Gallagher, MA
Listen
0:00 / 0:00

Key Takeaways

  • Universal adult HBV screening remains inconsistent in primary care, driving missed diagnoses; EHR triple-panel order sets and automated inpatient/ED screening with navigators can improve capture and linkage.
  • Reflex quantitative HBsAg testing after positive surface antigen could identify functional-cure candidates earlier, but commercial lab build-outs and EHR integration barriers delay routine adoption.
SHOW MORE

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Quantitative hepatitis B surface antigen (HBsAg) testing is becoming a routine way to find patients who could be candidates for a functional cure of chronic hepatitis B (CHB), but gaps in screening, referral, and monitoring capacity may limit who benefits, according to participants at The American Journal of Managed Care®'s Population Health Roundtable in New York, New York.

The discussion preceded the October 20 FDA approval of bepirovirsen (Hibsago; GSK), the first antisense oligonucleotide for CHB.1 The treatment is indicated for adults without cirrhosis who are on suppressed antiviral therapy with HBsAg of 3000 IU/mL or less, and pooled phase 3 data showed functional cure in 19% of treated patients vs 0% of those given placebo.2 Faculty said the weekly injections and lab monitoring of bepirovirsen could strain health systems without specialty pharmacy and care coordination support.

Where Screening and Linkage to Care Break Down

Although the CDC recommends a universal one-time adult screening of hepatitis B,3 faculty said it rarely happens outside hepatology. One hepatologist described the pattern in referrals: "I'm getting referrals from people with elevated transaminases who have been screened for hepatitis C and not hepatitis B."

One participant suggested an electronic health record (EHR) order set that bundles the full triple panel of surface antigen, surface antibody, and core antibody. Another cautioned about alert fatigue, and one health system scaled back hepatitis C screening pop-up prompts and moved reminders to a sidebar instead.

Su Wang, MD, MPH, FACP, of RWJBarnabas Health, described a model that sidesteps primary care gaps: automated surface antigen screening in emergency departments and hospitals, paired with patient navigators. The program has relied on grant funding and local champions. "You get this one-on-one navigator who has been able to get 80% to 90% of people into care. I think that's a good approach," she said.

Panelists discussed asking commercial laboratories to build reflex quantitative HBsAg testing after a positive surface antigen result, although one participant noted this can be difficult to set up. Without it, patients managed in primary care may never learn whether they are candidates for the functional cure.

How Specialists Are Using Quantitative HBsAg Testing

Participants

  • Tatyana Kushner, MD, MSCE, Weill Cornell Medicine (moderator)
  • Kristina Chacko, MD, FAASLD, Montefiore-Einstein Center for Transplantation
  • Ype P. de Jong, MD, PhD, Weill Cornell Medicine
  • Saikiran M. Kilaru, MD, NYU Langone Health
  • Tibor Krisko, MD, Weill Cornell Medicine
  • Mark Makhinson, PharmD, Mount Sinai Health System
  • Rebecca Roediger, MD, Weill Cornell Medicine
  • Mark S. Sulkowski, MD, Johns Hopkins University School of Medicine
  • Su Wang, MD, MPH, FACP, RWJBarnabas Health

Few patients arrive at specialty clinics with a quantitative HBsAg result, the specialists said. Mark S. Sulkowski, MD, of Johns Hopkins University School of Medicine, has tested patients at initial evaluation and annually for 4 years and said the result shows how close treated patients may be to functional cure. Ype P. de Jong, MD, PhD, of Weill Cornell Medicine, now orders it at return visits for all patients with CHB.

One panelist said that once the test is available in the EHR, ordering is simple, but it did take his health system nearly 2 years to get it added. Another said that having to order through commercial laboratories had limited how often he tested.

Because participants in the phase 3 trial for bepirovirsen had to be on nucleos(t)ide analogue (NA) therapy, faculty said they are starting NAs in gray-zone patients with low HBsAg who previously declined treatment. Several also treat beyond guideline thresholds, calling alanine aminotransferase (ALT) cutoffs outdated and weighing fibrosis, age, viral load, and family history of liver cancer instead.

What Weekly Bepirovirsen Monitoring Demands From Health Systems

Patients used to a daily pill and twice yearly visits will face about 6 months of weekly injections and labs to monitor ALT flares and low platelet counts once on bepirovirsen. Mark Makhinson, PharmD, of Mount Sinai Health System, noted that most of the large health systems at the roundtable, in the New York–New Jersey area, have robust specialty pharmacy programs that handle prior authorization, financial assistance, and monthly adherence checks through in-house specialty pharmacies.

"I think it's really positive, but...that is likely not the norm everywhere," Makhinson said.

Sulkowski said the group is working to rebuild the hepatitis C–era pharmacy partnerships that have largely been dismantled and to concentrate prescribing among a few bepirovirsen champions rather than all 15 clinicians who treat hepatitis B. Advanced practice providers would handle follow-up, with 340B Drug Pricing Program revenue justifying the hires. Wang suggested standing weekly lab orders, telehealth support, and ECHO-style learning networks to extend capacity beyond specialists.

A roughly 1-in-5 chance of functional cure is progress, the participants said, but it calls for candid conversations with patients about the odds. One panelist wants real-world data in their own patient population before committing patients to roughly 20% odds of cure. Wang said one benefit goes unmeasured in trials: relief from the stigma of living with hepatitis B.

"Patients, they feel infectious; [then] they worry about giving it to their family members, and there's a shame about that," Wang said. "Being able to say, 'I lost my surface antigen' is very liberating for them."

References

  1. McCormick B. Bepirovirsen approval offers new option for chronic HBV treatment. AJMC®. October 21, 2026. Accessed November 17, 2026. https://www.ajmc.com/view/bepirovirsen-approval-offers-new-option-for-chronic-hbv-treatment
  2. Hou J, Lim SG, Buti M, et al. Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection. N Engl J Med. 2026;394(24):2395-2406. doi:10.1056/NEJMoa2515131
  3. Hepatitis B Foundation. U.S. screening recommendations. Accessed November 17, 2026. https://www.hepb.org/prevention-and-diagnosis/u-s-screening-recommendations/

Related to this article